title: [Utrophin, a way to cure Duchenne muscle dystrophy].
abstract: Duchenne muscle dystrophy results from the absence of dystrophin, a cytoskeletal protein of the muscle fibre. Dystrophin plays an essential role in the integrity of the membrane-associated protein complexes connected to the extracellular matrix. On chromosome 6 is located the gene of a protein presenting 80 % homology with dystrophin : utrophin, which is expressed at the neuromuscular junction. The review examines if utrophin can replace dystrophin and correct the structural and functional characteristics of the myopathy, and how the improvements can be quantitatively expressed. In transgenic mice, deficient in dystrophin, but overexpressing large quantities of utrophin, the latter is found on structures where dystrophin is normally located, histological signs of necrosis disappear and the recovery of functional disorders, specially affecting the mechanical properties of the muscle fibres, can be complete. The review examines also several ways of obtaining overexpression of utrophin in adult mdx mice, such as conditioned expression of the utrophin transgene (using a tetracycline-sensitive transactivator), transfection with viral vectors containing the utrophin cDNA (complete or truncated), actions on factor(s) controlling utrophin expression at the neuromuscular junction (heregulin, 4 N-acetylgalactosamine), and pharmacological ways of inducing expression (NO, arginine). Though partial improvements of the myopathy status have been obtained by these various approaches, they remain limited by their localized action and/or by the moderate level of utrophin expression obtained. Further researchs to overcome these limitations are urgently needed in order to transform the very promising effect of utrophin overexpression into a real treatment of Duchenne myopathy.
authors.affiliation: Département de physiologie, Université Catholique de Louvain, UCL 5540, avenue Hippocrate, 55, 1200 Bruxelles, Belgique. gillis@fymu.ucl.ac.be
authors.forename: Jean-Marie
authors.initials: JM
authors.lastname: Gillis
mesh_terms: D000818:Animals; D003598:Cytoskeletal Proteins / Q000096:biosynthesis / Q000737:chemistry / Q000235:genetics / Q000502:physiology*; D018076:DNA, Complementary / Q000235:genetics; D016189:Dystrophin / Q000737:chemistry / Q000172:deficiency; D005786:Gene Expression Regulation / Q000187:drug effects; D015316:Genetic Therapy; D005822:Genetic Vectors / Q000627:therapeutic use; D006801:Humans; D008565:Membrane Proteins / Q000096:biosynthesis / Q000737:chemistry / Q000235:genetics / Q000502:physiology*; D051379:Mice; D018101:Mice, Inbred mdx; D018345:Mice, Knockout; D008822:Mice, Transgenic; D009137:Muscular Dystrophy, Animal / Q000235:genetics / Q000628:therapy; D020388:Muscular Dystrophy, Duchenne / Q000235:genetics / Q000628:therapy*; D020890:Neuregulin-1 / Q000627:therapeutic use; D009569:Nitric Oxide / Q000502:physiology; D020030:Nitric Oxide Donors / Q000627:therapeutic use; D011993:Recombinant Fusion Proteins / Q000502:physiology; D017386:Sequence Homology, Amino Acid; D015533:Transcriptional Activation; D049411:Utrophin
chemical_list: D003598:Cytoskeletal Proteins; D018076:DNA, Complementary; D016189:Dystrophin; D008565:Membrane Proteins; D020890:Neuregulin-1; D020030:Nitric Oxide Donors; D011993:Recombinant Fusion Proteins; C483600:Utrn protein, mouse; D049411:Utrophin; D009569:Nitric Oxide